Skip to main content
HVIVO PLC logo

HVIVO PLC — Investor Relations & Filings

Ticker · HVO ISIN · GB00B9275X97 LEI · 213800VT5KBM7JLIV118 IL Professional, scientific and technical activities
Open in API
Filings indexed 758 across all filing types
Latest filing 2024-11-06 Major Shareholding Noti…
Country GB United Kingdom
Listing IL HVO

About HVIVO PLC

https://hvivo.com/

hVIVO plc is a full-service contract research organization (CRO) and a leading specialist in human challenge trials. The company provides end-to-end clinical development solutions for a global biopharma client base, focusing on infectious and respiratory diseases. Its services span from preclinical consultancy to Phase III clinical trials, including first-in-human studies, biometry, and consulting. hVIVO operates a state-of-the-art quarantine facility in London and provides advanced laboratory services under its hLAB brand. Through subsidiaries such as CRS and Venn Life Sciences, it offers early-phase clinical trial expertise and patient recruitment across multiple clinical sites. The company's integrated approach is designed to accelerate the development of vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with 'RNS Number : 0562L' and contains the standard header 'National Storage Mechanism'. The content is a 'TR-1: Standard form for notification of major holdings', detailing an acquisition of voting rights by Octopus Investments Limited, crossing a threshold. This type of mandatory disclosure regarding significant changes in share ownership is classified as a Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-11-06 English
Presentation at Jefferies London Healthcare Conf
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 8669K' and contains an announcement from hVIVO plc stating that its CEO will be presenting at the Jefferies London Healthcare Conference. This is a corporate update regarding investor relations activities (a presentation at a conference) rather than a formal financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). Since it is a general announcement distributed via RNS (Regulatory News Service) that doesn't fit into the more specific categories like ER, IP, or CT, the most appropriate classification is the general regulatory announcement category, RNS, as it is a standard market communication.
2024-11-05 English
Long Term Incentive Plan/ PDMR Notification
Director's Dealing Classification · 98% confidence The document is an official announcement released via RNS (Regulatory News Service) on October 11, 2024. The content explicitly details the granting of Long Term Incentive Plan (LTIP) options to the CEO and senior employees. This type of disclosure, concerning transactions by Persons Discharging Managerial Responsibilities (PDMRs) regarding their holdings or awards, is a specific regulatory requirement often related to insider trading rules (MAR). While it involves director/executive dealings (DIRS) and remuneration (DEF 14A), the primary context is the mandatory public disclosure of these transactions, which falls under the scope of general regulatory announcements. Since the document is a formal notification of an event (granting options) and includes the standard RNS boilerplate and MAR declaration, it fits best as a general Regulatory Filing (RNS) or potentially DIRS. Given the structure and the explicit mention of RNS as the provider, RNS is a strong candidate, but the core subject matter is the transaction by a director. Comparing DIRS (Director's Dealing) and RNS (General Regulatory Filings), DIRS is more specific to the content (PDMR notification). However, the document structure strongly resembles a standard RNS announcement, which often serves as the vehicle for DIRS disclosures. Since the document is a full disclosure of the transaction details (price, volume, date) for the CEO, it is a specific type of insider transaction report. In many classification schemes, specific insider transaction reports are categorized separately. Given the options, 'DIRS' (Director's Dealing) is the most precise fit for the subject matter (PDMR notification regarding option awards), even though it is delivered via the RNS system.
2024-10-11 English
Positive results from RSV human challenge trial
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated October 7, 2024, originating from hVIVO plc and distributed via RNS (Royal National System/Regulatory News Service). It details positive results from a human challenge trial conducted by hVIVO for a client (Enanta Pharmaceuticals) regarding an RSV antiviral candidate (EDP-323). The structure, use of RNS Number, and the nature of the content (a company update on a specific event/result, not a full financial report like 10-K or IR) strongly suggest a general regulatory announcement. Since it is not a specific financial report, management change, dividend notice, or proxy statement, and it is distributed via RNS, the most appropriate classification is the general regulatory announcement category, RNS.
2024-10-07 English
Launch of full suite of hLAB standalone services
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 8781F' and contains information typical of a regulatory news service announcement, including company details, a date (30 September 2024), and contact information for brokers and PR firms. The content announces the 'Official launch of full suite of hLAB standalone services' and the receipt of HSE clearance for a CL-3 laboratory. This is a specific operational and business update, not a comprehensive annual report (10-K), an earnings release (ER), or a formal shareholder vote result (DVA). Since it is a general, material announcement distributed via RNS that doesn't fit the more specific categories like MANG, CAP, or DIV, the most appropriate classification is the general Regulatory Filings category (RNS), as it is explicitly distributed through the RNS system and serves as a broad announcement mechanism.
2024-09-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled as 'RNS Number : 3042F' and contains a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership (crossing thresholds). The definition for 'Major Shareholding Notification' is 'MRQ'. Although the document is distributed via RNS (Regulatory Filings), the specific content dictates the classification as MRQ, as it is a standardized regulatory filing for major holdings, not a general announcement.
2024-09-24 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.